Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Scandion Oncology, Audiocast with teleconference, Q1'24

By Inderes5/22/2024, 8:00 AM
Scandion Oncology

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Francois Martelet
00:00 - 10:24

Go ahead. Thank you very much, and welcome to this Q1 2024 conference call, in which we will be reporting our progress of the last quarter. Next slide please. So this is a disclaimer slide that I will not ask you to read, obviously. Next slide please. Today I will go through the quarter overview and our results. I will also have some remarks about the PANTAX final data. And then Johnny will address the financial performance of the company. And then I will make some closing remarks summarizing where we stand and where we will be as a company. Next slide please. Before I go into the overview and review, I just would like to mention again that we are a very small team of senior-level executives, all of us with extensive experience in biopharma, pharma, and biotechnology. And then I would like to mention that we have a very strong clinical advisory board, especially Professor Bernie Rose. Some of you may have watched the interview he gave us during the R&D day we just had a few days ago in Stockholm that was broadcasted as well. So I would like to also mention that we have added two leading oncologists. Professor Pfeiffer from Copenhagen and Professor Michel Ducreux from Paris. Both are leading European clinical oncologists in the field of GI gastrointestinal diseases. And therefore, we are very well equipped to be advised on any future design of our clinical trials and also on how that will converge to what we call Scandion Oncology's next steps. Next slide please. So this is a slide that shows you the overview of our pipeline. And I would like to mention SCO-101, which is our lead compound that most of you know, is addressed in colorectal cancer and pancreatic cancer, not mentioned in gastric cancer as well. I would like to spend just one minute on SCO-201, SCO-201 is our follow-up compound and is currently on hold from a development perspective. Not because it is a bad compound, but because we need to make some prioritizations and that compound may be studied further in HIV/solid tumors. So to come back on SCO-101, so you see the clearest data, you see that we will be releasing the final data of the trial, part three, in H2 2024. With regard to contacts you have, some of you have noticed that we have released the final data a few days ago, actually. And I will come back to that as well. And, not to mention again, gastric cancer where we have good preclinical data and are what we call Phase 1B/2A ready. So this is the pipeline that fundamentally consists of our lead compound, SCO-101. Next slide please. These are the results of part three. And I would like you to pay a little bit of attention to that. Regarding the trial part three, we have observed in six patients two partial responses, meaning that the tumor shrinkage or the tumor reduction was more than 30%. And this is actually quite outstanding by all metrics in late-stage colorectal cancer patients. If you compare that number to a recent study, then you will find a 6% tumor reduction. Of course, our results need to be confirmed in a randomized clinical trial. But at least, no one can argue that we have had very good signs of clinical efficacy. At the same time, we had the CBR. So, the clinical benefit rate is 76% after eight weeks. And, if you compare it to another study that has been reported, the data is very good. Even more importantly, we have a promising median overall survival of close to eight months and a median progression-free survival of about 3.8 months. If you compare this progression-free survival (PFS). Free survival, with another study that has been recently released. Then, you get a number less than two months. So again, no one can argue that we haven't released significant data. We are really the company in drug resistance showing some significant data out of this phase IIa. And then finally, because we all know that the regulatory authorities will never accept any clinical development without a significant biomarker, we have been able to identify a biomarker for our next step and down the road, a randomized clinical trial called UGT1A1. And if we select patients with this biomarker, wildtype patients with colorectal cancer, then you get a median overall survival. Even better, a longer median overall survival of close to actually 14 months. And again, if you compare it to a recent study, yes, with many more patients, but still you only get a median of close to 11 months. So we have really good signs of clinical efficacy that I would like to also show you on the next slide. And this is a very important slide. And I couldn't resist showing it to you. You know, this is a 55-year-old female with RAS-mutated colon cancer, whom we have been treating since August 23rd, and she is still alive. And on the left-hand side, you could see, when we started the treatment, so you could see the tumor on the scan, quite a large one. And then, from August until December, you could see the very significant tumor shrinkage. That patient is still alive. That patient has a partial response. So this is what I wanted to show you as an example of our clinical efficacy. Now, furthermore, it's important to note that the other patients also had tumor shrinkage but with a lesser magnitude, between 6 and 25%, not reaching the 30% threshold. But still, we observed tumor reduction. Next slide, please. So if I could summarize very quickly, in parts one, two, and three; we could easily state we have a good safety and tolerability profile. Partial responses in two patients in the last cohort, of the six patients with a dosage of 250 mg on a four-day schedule, we have an impressive overall survival. Between 8 and 10 months. We have seen a significant increase in overall survival in a subgroup of patients expressing wildtype UGT1A1, from eight months to more than 30 months. And then, you know, what does that mean? That means that this data justifies the expansion of our series. Part three. And we need to enroll a small patient cohort in order to look at the maximum tolerated dose and examine the dosing regimen. So that will be further applied in a randomized clinical trial. Yes. Uh, the next slide will show you, uh, the data that has been recently released with regard to pancreatic cancer. Contacts with one being the maximum tolerated dose achieved is 200mg of alcoholic compounds. Uh, the PK data demonstrated that SCO-101 exposure is in line with our expectations. We had a partial response, and we had an overall response rate of 6.7% with a good CBR. Uh, progression-free survival was 2.5 months. Overall survival was 9.5 months. And, um, I have to say that, uh, these results are pretty good. And, uh, if we don't pursue the clinical development of pancreatic cancer, it's not because we lack the data; it's because we need to prioritize our relatively small level of resources onto colorectal cancer. And I think with that said, I will now pass the word to our dear CFO, Johnny. The floor is yours. Thank you. And if you look at this slide with the financial overview.

Johnny Stilou
10:24 - 12:50

You can see that the results of the quarter was a net loss of 7.5 million Danish kroner. This compares to a loss of 9.3 million in the previous Q1 quarter of last year, 2023. The quarter ended with a cash position of 16.9 million Danish kroner. Overall, the result is in line with our expectations and once again, it reflects our continued focus on reducing our costs. And if we look at the next slide at the bottom, you can see that over the past eight quarters, our overall cost base has declined. Q1 2024 is the lowest quarterly cost we have had. And we do expect as our clinical programs progress, and we continue to focus, that our quarterly cost base will continue to be reduced over the coming quarters. So with that in mind, our current funds can fund operations into Q2 of 2025 as a going concern. Now, I will just quickly give you an update on the ongoing rights issue. Uh, some important dates here. Uh, as you recall this a couple of times, uh, the subscription price period. We are in the middle of that now, and it runs until tomorrow, May 23rd and the following, uh, that tomorrow we will publish the final terms of the rights issue. Around June 3rd, the prospectus will be made public, following which the trading and subscription period starts in the period between June 5th to June 17th. You can trade in the unit rights with your bank in the same period plus three days. So from June 5th to June 20th, the subscription period is open where you can subscribe for the shares in the rights issue. And again, you can do this with your bank. Thank you. With that, I will give the word back to the host for closing remarks. Thank you.

Francois Martelet
12:50 - 17:12

Johnny, this slide does show you what you can expect from Scandion Oncology A/S during the second part of the year as we approach H2. First of all, we will be releasing the final data readout, part three. And that's an important data release. That will happen before year end. And then we will be releasing the top line of the next step. You see, this is the small study that we will embark on following the successful completion of the rights issue. And we expect to release that around year end. So it could be slightly before or slightly after. Next slide please. To summarize, I would like to mention that on the corporate side, we will certainly continue to maximize our runway as Johnny mentioned. We will continue to reap the benefits of our change of communication with regard to the paradigm of our technology. We are a drug efflux pump inhibition company, and this is very important. We are not a chemotherapy company or a generic company. We are an efflux pump inhibition company. We will therefore increase the focus on presentations to investors and potential partners, as we have been starting quite some time ago. And then obviously, by executing this small bridge study that will determine the MTD and strengthen the data package. We will be in a far better position to find a partner on the scientific and medical side, as it was mentioned before. I would just like to add that we have been scheduling a global scientific advisory board in colorectal cancer. We had one in December. We will repeat that one with US investigators this time. And also we will be preparing the randomized phase 2B/3 study in colorectal cancer. So, next slide to summarize our strengths. We are a precision anti-cancer drug company. We are one of the first companies addressing drug resistance in oncology. We have this dual mechanism of action that I didn't need to remind some of you about because it has been mentioned before, targeting CB2 and UGT1A1. And certainly we are one of the first movers in targeting cancer drug resistance. Needless to say, colorectal cancer is a deadly disease. At the survival rate at five years at the metastatic stage is about 12%. Unfortunately, when this diagnosis is made, the majority of the patients, more than 50%, are already at the metastatic stage. So there is obviously a great market potential for our drug in this particular market. Johnny mentioned that we will be continuing to maximize the runway by controlling our costs quite drastically, which is the obsession of a good CFO and a good CEO. I think in biotech, as you see, we are very strongly focused. We will be dedicating our resources to the next step. We, uh, I hope I was able to demonstrate that we are a very small team of very senior executives, and we are helped and assisted by the best-in-class, by all standards, clinical advisory boards. As I mentioned before, earlier in my presentation, at a very critical inflection point, I discussed the Next Step study and the final Phase three results. Now, having said that, I would like to thank you for your choice and commitment to your patients, as well as mentioning that we are today in the most favorable position in the history of Scandion. Having said that, thank you very much. And back to the operator now for Q&A.

Operator
17:14 - 17:22

Thank you. And the first question comes from the line of Christian Binder from Redeye. Please go ahead. Your line is open. But.

Unknown 1
17:24 - 17:55

Hi and thank you so much for taking my questions. I have two, if that's okay. First off, you already showed, you know, this timeline in terms of when you're going to have the Part three expansion cohort, topline data. And you mentioned that it could vary by a couple of months, but I guess depending on when the readout comes, it's not necessarily going to affect your timeline for Phase three. Can you elaborate on how the details are going to affect your timeline for the coming trial?

Francois Martelet
17:56 - 18:57

Yeah, totally. Thank you for asking this question. Well, you know, as I said earlier, we will be embarking as soon as the right issue is successfully completed on this bridge study that will be looking at MTD and, looking at the details in order to strengthen our package, we will be also looking at partners, you see, and once this is done as I mentioned earlier, we will get the topline results. But at the same time, you know, we need to wait a bit of time to be able to get the overall survival. So would that influence the start of the CRC Phase 2B/3? Probably not. But the fundamental question is that we need a partner in order to perform that study. Absolutely. Given the magnitude of the size of it, if you compare to what has been published recently in literature, we are talking about 500 to 700 patients.

Unknown 1
18:59 - 19:21

All right. Perfect. It's very helpful. And, my other question would be, if I understood it correctly, about 50% of your rights issue is guaranteed. In case we come close to around 100% subscription. Is that going to affect your timeline for Phase 2B in terms of preparations and other activities?

Johnny Stilou
19:23 - 19:56

Who is correctly stated that around 50% is guaranteed. If we get a subscription higher than 50%, that will not enable us to start. The Phase three randomized study. However, it will extend our runway and will enable us to start the preparations needed for the Phase two study.

Unknown 1
19:58 - 20:01

All right. Perfect. That was all from me. Thank you so much.

Francois Martelet
20:02 - 20:02

Thank you.

Operator
20:04 - 20:10

There are no more questions from the teleconference, so I hand the word back to you, Francois and Gianni, for any closing comments.

Francois Martelet
20:11 - 20:37

Thank you very much. So I hope, you know, we were able to show you today that we are indeed in the most favorable position in the history of Scandion Oncology, given the kind of data we've been able to release, and we look forward to completing the rights issue and to starting the strongest possible, our upcoming British study. Thank you so much again. And, uh, speak to you soon.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…